What question did this study set out to answer?

To review major classes of therapeutic nanoparticles, evaluate their clinical applications across diverse disease domains, and analyze safety and regulatory hurdles affecting clinical translation.

August 16, 2026Nano LIFE

Review of Nanoparticle-Based Therapeutics: Comparative Clinical Translation, Safety Barriers, and Regulatory Challenges

View Full Paper

Ask AI

Bookmark

Authors

AEAlaa A. El-Said SGSara K. Ghodeif NENahla S. El‐Shenawy

Discussion

Member takes

Overview

Review outlines translational hurdles and safety profiles of nanoparticle therapeutics across major disease models, highlighting pathways toward standardized clinical regulation.

Key Points

To review major classes of therapeutic nanoparticles, evaluate their clinical applications across diverse disease domains, and analyze safety and regulatory hurdles affecting clinical translation.
Narrative review synthesizing evidence on major nanoparticle platforms, including lipid-based, polymeric, metallic, magnetic, and carbon-based formulations.
Evaluated therapeutic delivery applications across oncology, infectious disease, neurology, and cardiovascular medicine alongside associated toxicological and regulatory frameworks.
Nanoparticles spanning 1 to 100 nm enhance targeted drug delivery and therapeutic efficacy while substantially mitigating systemic toxicity compared to conventional formulations.
Clinical adoption remains constrained by biological safety concerns, long-term biocompatibility barriers, and complex regulatory approval pathways across diverse nanomedicine platforms.

Cite This Study

El-Said et al. (2026) studied this question.

synapsesocial.com/papers/6a8179bcf2fb91fc834acfe1 https://doi.org/10.1142/s1793984426300189

View Full Paper

Ask AI

Bookmark

August 16, 2026Nano LIFE

Review of Nanoparticle-Based Therapeutics: Comparative Clinical Translation, Safety Barriers, and Regulatory Challenges

View Full Paper

Ask AI

Bookmark

Authors

AEAlaa A. El-Said SGSara K. Ghodeif NENahla S. El‐Shenawy

Discussion

Member takes

Overview

Review outlines translational hurdles and safety profiles of nanoparticle therapeutics across major disease models, highlighting pathways toward standardized clinical regulation.

Key Points

To review major classes of therapeutic nanoparticles, evaluate their clinical applications across diverse disease domains, and analyze safety and regulatory hurdles affecting clinical translation.
Narrative review synthesizing evidence on major nanoparticle platforms, including lipid-based, polymeric, metallic, magnetic, and carbon-based formulations.
Evaluated therapeutic delivery applications across oncology, infectious disease, neurology, and cardiovascular medicine alongside associated toxicological and regulatory frameworks.
Nanoparticles spanning 1 to 100 nm enhance targeted drug delivery and therapeutic efficacy while substantially mitigating systemic toxicity compared to conventional formulations.
Clinical adoption remains constrained by biological safety concerns, long-term biocompatibility barriers, and complex regulatory approval pathways across diverse nanomedicine platforms.

Cite This Study

El-Said et al. (2026) studied this question.

synapsesocial.com/papers/6a8179bcf2fb91fc834acfe1 https://doi.org/10.1142/s1793984426300189

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark